Etoposide

From Wikipedia, the free encyclopedia

Etoposide
Systematic (IUPAC) name
4'-demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside], 4' -(dihydrogen phosphate)
Identifiers
CAS number 33419-42-0
ATC code L01CB01
PubChem 36462
DrugBank APRD00239
Chemical data
Formula C29H32O13 
Mol. mass 588.557 g/mol
Pharmacokinetic data
Bioavailability Highly variable, 25 to 75%
Protein binding 97%
Metabolism Hepatic (CYP3A4 involved)
Half life Oral: 6 h., IV: 6-12 h., IV in children: 3 h.
Excretion Renal and fecal
Therapeutic considerations
Pregnancy cat.

D(AU) D(US)

Legal status

POM(UK) -only(US)

Routes Oral, intravenous

Etoposide phosphate (brand names: Eposin, Etopophos, Vepesid, VP-16) is an inhibitor of the enzyme topoisomerase II. It is used as a form of chemotherapy for malignancies such as Ewing's sarcoma, lung cancer, testicular cancer, lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme. It is often given in combination with other drugs.

Chemically it derives from podophyllotoxin, a toxin found in the American Mayapple.

[edit] Administration

It is given intravenously or orally in capsule form. If the drug is given by IV it must be done slowly over a 30 to 60 minute period because it can lower blood pressure as it is being administered. Blood pressure is checked often during infusing with the speed of administration adjusted accordingly.

Patients are generally advised to call their doctor in case of fever, symptoms of infection or painful injection sites, as these may progress severely without adequate medical attention.

Patients are advised to drink large amounts of fluids after treatment to prevent damage to the bladder and kidneys, typically 1.5 to 3.5 litres of water on the day of treatment and for several days after.

[edit] Side effects

Common are:

Less common are:

[edit] External links